GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) » Definitions » Capex-to-Revenue

Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Capex-to-Revenue : 0.02 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Gulf Pharmaceutical Industries PSC Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Gulf Pharmaceutical Industries PSC's Capital Expenditure for the three months ended in Dec. 2023 was د.إ-9.50 Mil. Its Revenue for the three months ended in Dec. 2023 was د.إ412.60 Mil.

Hence, Gulf Pharmaceutical Industries PSC's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.02.


Gulf Pharmaceutical Industries PSC Capex-to-Revenue Historical Data

The historical data trend for Gulf Pharmaceutical Industries PSC's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gulf Pharmaceutical Industries PSC Capex-to-Revenue Chart

Gulf Pharmaceutical Industries PSC Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.03 0.04 0.04 0.02

Gulf Pharmaceutical Industries PSC Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.01 0.02 0.02 0.02

Competitive Comparison of Gulf Pharmaceutical Industries PSC's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Gulf Pharmaceutical Industries PSC's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gulf Pharmaceutical Industries PSC's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gulf Pharmaceutical Industries PSC's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gulf Pharmaceutical Industries PSC's Capex-to-Revenue falls into.



Gulf Pharmaceutical Industries PSC Capex-to-Revenue Calculation

Gulf Pharmaceutical Industries PSC's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-27) / 1638
=0.02

Gulf Pharmaceutical Industries PSC's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-9.5) / 412.6
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gulf Pharmaceutical Industries PSC  (ADX:JULPHAR) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Gulf Pharmaceutical Industries PSC Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gulf Pharmaceutical Industries PSC's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Business Description

Traded in Other Exchanges
N/A
Address
Airport Road, P.O. Box 997, Digdaga, Ras Al Khaimah, ARE
Gulf Pharmaceutical Industries PSC is a generic pharmaceutical manufacturer in the Middle East and North Africa. The company manufactures and sells pharmaceuticals and medical compounds, including cosmetics compounds, and drugs. It operates in four segments: Manufacturing, Planet, Investments, and others. It maintains a diverse product portfolio that targets various therapeutic segments including Gastrointestinal Tract (GIT), Respiratory, Pain Management, Wounds & Scars, Anti-infectives, Anemia, Gynecology, Dermatology, Erectile Dysfunction, and Cardiology. The geographical segments are UAE, Other GCC countries, and Other countries.

Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Headlines

No Headlines